Lago F, Dieguez C, G’omez-Reino JG, Gualillo O. The emerging role of adipokines as mediators of inflammation and immune responses. Cytokine Growth Factor Rev. 2007;18:313–25.
Article
CAS
Google Scholar
Kraszula L, Jasi’nska A, Eusebio MO, Kuna P, Głabi’nski A, Pietruczuk M. Evaluation of the relationship between leptin, resistin, adiponectin and natural regulatory T cells in relapsing-remitting multiple sclerosis. Neurol Neurochir Pol. 2012;46(1):22–8.
Article
CAS
Google Scholar
Emamgholipour S, Eshaghi SM, Hossein-nezhad A, Mirzaei K, Maghbooli Z, Sahraian MA. Adipocytokine profile, cytokine levels and Foxp3 expression in multiple sclerosis: a possible link to susceptibility and clinical course of disease. PLoS ONE. 2013;8(10):e76555.
Article
CAS
Google Scholar
Koerner A, Kratzsch J, Kiess W. Adipocytokines: leptin—the classical, resistin—the controversial, adiponectin—the promising, and more to come. Best Pract Res Clin Endocrinol Metab. 2005;19(4):525–46.
Article
CAS
Google Scholar
Natarajan R, Hagman S, Hämälainen M, Leppänen T, Dastidar P, Moilanen E, et al. Adipsin is associated with multiple sclerosis: a follow-up study of adipokines. Mult Scler Int. 2015;2015:371734–42.
PubMed
PubMed Central
Google Scholar
Francisco V, Pino J, Campos-Cabaleiro V, Ruiz-Fernández C, Antonio MA, Gonzalez-Gay MA, et al. Obesity, fat mass and immune system: role for leptin. Front Physiol. 2018;9:640.
Article
Google Scholar
Meier U, Gressner A. T1 endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and resistin. Clin Chem. 2004;50(9):1511–25.
Article
CAS
Google Scholar
Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol. 2006;6(10):772–83.
Article
CAS
Google Scholar
Paul A, Comabella M, Gandhi R. Biomarkers in Multiple sclerosis. Cold Spring Harb Perspect Med. 2019;9(3):a029058.
Article
CAS
Google Scholar
Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162–73.
Article
Google Scholar
Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444–52.
Article
CAS
Google Scholar
Roxburgh RH, Seaman SR, Masterman T, Hensiek AE, Sawcer SJ, Vukusic S, et al. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology. 2005;64(7):1144–51.
Article
CAS
Google Scholar
Xie XF, Huang XH, Shen AZ, Li J, Sun YH. Association between circulating leptin levels and multiple sclerosis: a systematic review and meta-analysis. Postgrad Med J. 2018;94:278–83.
Article
CAS
Google Scholar
Hietaharju A, Kuusisto H, Nieminen R, Vuolteenaho K, Elovaara I, Moilanen E. Elevated cerebrospinal fluid adiponectin and adipsin levels in patients with multiple sclerosis: a Finnish co-twin study. Eur J Neurol. 2010;17(2):332–4.
Article
CAS
Google Scholar
Palavra F, Marado D, Mascarenhas-Melo F, Sereno J, Teixeira-Lemos E, Nunes CC, et al. New markers of early cardiovascular risk in multiple sclerosis patients: oxidized-LDL correlates with clinical staging. Dis Markers. 2013;34(5):341–8.
Article
CAS
Google Scholar
Musabak U, Demirkaya S, Genc G, Ilikci RS, Odabasi Z. Serum adiponectin, TNF, IL-12p70, and IL-13 levels in multiple sclerosis and the effects of different therapy regimens. Neuro Immuno Modulation. 2011;18(1):57–66.
CAS
Google Scholar
Penesova A, Vlcek M, Imrich R, Vernerova L, Marko A, Meskova M, et al. Hyperinsulinemia in newly diagnosed patients with multiple sclerosis. Metab Brain Dis. 2015;30:895–901.
Article
CAS
Google Scholar
Çoban A, Düzel B, Tüzün E, Tamam Y. Investigation of the prognostic value of adipokines in multiple sclerosis. Mult Scler Relat Disord. 2017;15:11–4.
Article
Google Scholar
Signoriello E, Lus G, Polito R, Casertano S, Scudiero O, Coletta M, et al. Adiponectin profile at baseline is correlated to progression and severity of Multiple Sclerosis. Eur J Neurol. 2019;26(2):348–55.
Article
CAS
Google Scholar
Eftekhari E, Etemadifar M, Ebrahimi A, Baradaran S. The relation between peptide hormones and sex hormone in patients with multiple sclerosis. Iran J Neurol. 2013;12:60–5.
PubMed
PubMed Central
Google Scholar
Frisullo G, Mirabella M, Angelucci F, Caggiula M, Morosetti R, Sancricca C, et al. The effect of disease activity on leptin, leptin receptor and suppressor of cytokine signalling-3 expression in relapsing-remitting multiple sclerosis. J Neuroimmunol. 2007;192:174–83.
Article
CAS
Google Scholar
Evangelopoulos ME, Koutsis G, Markianos M. Serum leptin levels in treatment-naive patients with clinically isolated syndrome or relapsing-remitting multiple sclerosis. Autoimmune Dis. 2014;2014:1–6.
Article
Google Scholar
Kolić I, Stojković L, Dinčić E, Jovanović I, Stanković A, Živković M. Expression of LEP, LEPR and PGC1A genes is altered in peripheral blood mononuclear cells of patients with relapsing-remitting multiple sclerosis. J Neuroimmunol. 2020;338:577090.
Article
Google Scholar
Saad MF, Damani S, Gingerich RL, Riad-Gabriel MG, Khan A, Boyadjian R, et al. Sexual dimorphism in plasma leptin concentration. J Clin Endocrinol Metab. 1997;82(2):579–84.
CAS
PubMed
Google Scholar
Rotondi M, Batocchi AP, Coperchini F, Caggiula M, Zerbini F, Sideri R, et al. Severe disability in patients with relapsing-remitting multiple sclerosis is associated with profound changes in the regulation of leptin secretion. NeuroImmunoModulation. 2013;20(6):341–7.
Article
CAS
Google Scholar
Messina S, Vargas-Lowy D, Musallam A, Healy BC, Kivisakk P, Gandhi R, et al. Increased leptin and A-FABP levels in relapsing and progressive forms of MS. BMC Neurol. 2013;13(1):172.
Article
Google Scholar
Kazemi MR, McDonald CM, Shigenaga JK, Grunfeld C, Feingold KR. Adipocyte fatty acid-binding protein expression and lipid accumulation are increased during activation of murine macrophages by toll-like receptor agonists. Arterioscler Thromb Vasc Biol. 2005;25:1220–4.
Article
CAS
Google Scholar
Wu DM, Shen MH, Chu NF. Relationship between plasma leptin levels and lipid profiles among school children in Taiwan–the Taipei Children Heart Study. Eur J Epidemiol. 2001;17(10):911–6.
Article
CAS
Google Scholar
Wannamethee SG, Tchernova J, Whincup P, Owe GD, Kelly A, Rumley A, et al. Plasma leptin: associations with metabolic, inflammatory and haemostatic risk factors for cardiovascular disease. Atherosclerosis. 2007;191(2):418–26.
Article
CAS
Google Scholar
Liuzzi A, Savia G, Tagliaferri M, Lucantoni R, Berselli ME, Petroni ML, et al. Serum leptin concentration in moderate and severe obesity: relationship with clinical, anthropometric, and metabolic factors. Int J Obes Relat Metab Disord. 1999;23:1066–73.
Article
CAS
Google Scholar
Ekmen N, Helvaci A, Günaldı M, Sasani H, Yildirmak S. Leptin as an important link between obesity and cardiovascular risk factors in men with acute myocardial infarction. Indian Heart J. 2016;68(2):132–7.
Article
Google Scholar
Biström M, Hultdin J, Andersen O, Alonso-Magdalena L, Jons D, Gunnarsson M, et al. Leptin levels are associated with multiple sclerosis risk. Mult Scler. 2020;27(1):19–27.
Article
Google Scholar
Batocchi A, Rotondi M, Caggiula M, Frisullo G, Odoardi F, Nociti N, et al. Leptin as a marker of multiple sclerosis activity in patients treated with interferon-beta. J Neuroimmunol. 2003;139:150–4.
Article
CAS
Google Scholar
Chatzantoni K, Papathanasopoulos P, Gourzoulidou E, Athanasia M. Leptin and its soluble receptor in plasma of patients suffering from remitting-relapsing multiple sclerosis (MS) In vitro effects of leptin on type-1 and type-2 cytokine secretion by peripheral blood mononuclear cells, T-cells and monocytes of MS patients. J Autoimmun. 2004;23:169–77.
Article
CAS
Google Scholar
Kvistad SS, Myhr KM, Holmøy T, Benth JŠ, Wergeland S, Beiske AG, et al. Serum levels of leptin and adiponectin are not associated with disease activity or treatment response in multiple sclerosis. J Neuroimmunol. 2018;15(323):73–7.
Article
Google Scholar
Lanzillo R, Carbone F, Quarantelli M, Bruzzese D, Carotenuto A, Rosa DE, et al. Immunometabolic profiling of patients with multiple sclerosis identifies new biomarkers to predict disease activity during treatment with interferon beta-1a. Clin Immunol. 2017;183:249–53.
Article
CAS
Google Scholar
Holmøy T, Løken-Amsrud K, Bakke S, Beiske A, Bjerve K, Hovdal H, et al. Inflammation markers in multiple sclerosis: CXCL16 reflects and may also predict disease activity. PLoS ONE. 2013;8:e75021.
Article
Google Scholar